Cleveland BioLabs, Inc. (
Dr. Michael Fonstein, Chief Executive Officer and President of Cleveland BioLabs, will give a presentation on November 27, at 8:00 a.m. EST on the Company's technology platform and lead products. The presentation will be followed by a question and answer session and a live webcast may be accessed at the Company's website, www.cbiolabs.com or at http://www.piperjaffray.com/conferences. A replay of the presentation will be archived for 30 days after the conference, at the same locations.
Cleveland BioLabs management will be available for meetings in New York on November 27-28.
The Company's platform technology utilizes proprietary knowledge regarding regulated cell death (apoptosis) to develop drugs which either temporarily suppress cell death in select tissues to protect from acute stresses such as radiation and ischemia (a condition in which blood flow, and thus oxygen, is restricted to a part of the body), or induce cell death to treat cancer.
Cleveland BioLabs currently has two lead compounds in late stages of development. Curaxin CBLC102 is an orally administered small molecule designed to kill tumor cells by simultaneously targeting two key regulators of apoptosis. The Company has an ongoing Phase II trial with CBLC102 in hormone refractory prostate cancer and will begin additional Phase II trials in Renal Cell Carcinoma and multiple cancer types in the coming months.
The Company's other lead compound, Protectan CBLB502, is a modified protein of a microbe that temporarily protects cells from regulated cell death. CBLB502 is the first compound of its kind to provide protection from both gastrointestinal and hematopoietic (bone marrow/blood production) radiation-induced damage.
Cleveland BioLabs submitted CBLB502 to the Department of Defense (DoD) in response to a Request for Proposal (RFP) for medical radiation countermeasures to treat gastrointestinal effects of acute radiation syndrome. The RFP award would provide funding for development of the countermeasure through FDA approval, leading to purchase of up to 500,000 doses, thereafter. The Company expects the DoD to make its decision on the RFP this year.
CBLB502 is undergoing an accelerated development program under the FDA two-animal rule, which requires demonstrations of efficacy in two animal species and only safety in humans. The Company recently announced the completion of Good Manufacturing Practices compliant (cGMP) manufacturing of Protectan CBLB502 and plans to submit an Investigational New Drug (IND) application to the FDA for a human safety study this year.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in our periodic filings with the Securities and Exchange Commission.
Contacts:
Rachel Levine
Director Corporate Development & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@hfgcg.com